Samsung Biologics is set to launch its next-generation contract development and manufacturing (CDMO) service standard, ExellenS, in Europe. The company intends to showcase how it has leveraged the expertise gained from operating its first four plants to enhance the manufacturing framework at its fifth plant. All future production facilities beyond the fifth plant will be standardized to ensure a rapid supply of biopharmaceuticals with consistently high quality across all sites.
Samsung Biologics Expands CDMO Business Operations in Europe
Industry sources reported on Friday that Samsung Biologics will take part in BioEurope 2025, Europe’s largest biopharmaceutical partnering event, scheduled to be held from November 3 to 5 in Vienna, Austria.
Now in its 31st year, BioEurope has established itself as a vital networking platform where over 5,500 pharmaceutical and biotech professionals from around the globe converge to share the latest technological trends and explore new business partnerships.
Samsung Biologics will operate a standalone booth at the event, aiming to showcase its impressive 784,000-liter production capacity along with its distinctive CDMO capabilities to global clients and potential partners.
By formally introducing ExellenS—its optimized biopharmaceutical manufacturing framework—to the European market, Samsung Biologics seeks to reinforce its position as a trusted industry partner.
Implementation of ExellenS at the Fifth Plant Enhances Competitiveness in Equivalence and Speed
ExellenS embodies Samsung Biologics’ commitment to swiftly delivering biopharmaceuticals of consistent quality to its customers, with equivalence and speed serving as the core values of its manufacturing framework.
This framework maximizes reliability, quality consistency, and operational efficiency in biopharmaceutical manufacturing. It represents the culmination of over a decade’s worth of expertise acquired from operating production facilities at the first four plants.
Standardization is the hallmark of ExellenS. The company has applied the know-how gained from its first four plants to improve the operations of its fifth plant (180,000 liters). Future production facilities will adopt a unified standard for core equipment, process functions, automation systems, and quality control measures.
Clients can expect biopharmaceuticals of consistent quality regardless of which plant handles production after the completion of the fifth plant.
Given that even minor environmental variations can affect biopharmaceutical quality, ensuring equivalence is crucial. Through the ExellenS framework, Samsung Biologics is able to offer clients predictable outcomes.
Samsung Biologics is also establishing an agile production system capable of rapidly supplying pharmaceuticals to meet global demand by leveraging the optimized production design and operational processes offered through ExellenS.
Building on these strengths, the company plans to hold business meetings with major European pharmaceutical and biotech ventures at BioEurope, emphasizing the advantages presented by the ExellenS platform.
Samsung Biologics aims to maintain its competitive edge as a top-tier global CDMO by integrating its four core values—customer satisfaction, operational excellence, superior quality, and outstanding employee capabilities (4E)—along with the principles of simplification, standardization, and scalability (3S).
An industry insider commented that in the biopharmaceutical CDMO business, consistent quality and speed are as critical as production capacity. The implementation of ExellenS at the fifth plant and future facilities underscores Samsung Biologics’ commitment to establishing a significant competitive advantage over its rivals.